Detalhe da pesquisa
1.
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.
Lancet
; 402(10419): 2295-2306, 2023 12 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37931632
2.
High risk of lung cancer in surfactant-related gene variant carriers.
Eur Respir J
; 63(5)2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38575158
3.
Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes.
Mol Cancer
; 22(1): 120, 2023 07 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37516818
4.
Evaluation of long-term sequelae by cardiopulmonary exercise testing 12 months after hospitalization for severe COVID-19.
BMC Pulm Med
; 23(1): 13, 2023 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36635717
5.
Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 23(9): 1180-1188, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35964621
6.
Prognostic value of CD4+ T lymphopenia in non-small cell lung Cancer.
BMC Cancer
; 22(1): 529, 2022 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35546670
7.
Impact of open-label versus blinded study design on patient-reported outcomes data in randomized clinical trials of immunotherapy in advanced or metastatic cancer patients: a systematic review.
Qual Life Res
; 31(3): 645-657, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34283382
8.
Feasibility of health-related quality of life (HRQoL) assessment for cancer patients using electronic patient-reported outcome (ePRO) in daily clinical practice.
Qual Life Res
; 30(11): 3255-3266, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-33387291
9.
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Cochrane Database Syst Rev
; 4: CD013257, 2021 04 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-33930176
10.
Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation.
Cancer Immunol Immunother
; 69(10): 1947-1958, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32676716
11.
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Cochrane Database Syst Rev
; 12: CD013257, 2020 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33316104
12.
Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+/TIM-3+ T cells in lung cancer.
Br J Cancer
; 121(5): 405-416, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31358938
13.
Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study.
Eur Respir J
; 51(3)2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29545318
14.
Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial.
Eur Respir J
; 52(4)2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30262574
15.
Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study.
BMC Cancer
; 18(1): 1013, 2018 Oct 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-30348130
16.
Thoracic CT follow-up after non-small-cell lung cancer resection - Authors' reply.
Lancet Oncol
; 23(11): e486, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36328015
17.
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).
Lancet
; 387(10026): 1415-1426, 2016 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-26777916
18.
EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice.
Eur Respir J
; 50(2)2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28798090
19.
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
Lancet Oncol
; 17(2): 212-223, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26727163
20.
Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy.
Eur Respir J
; 48(3): 861-72, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27338193